Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140275482Abstract: Compounds for UV-Vis detectable incorporation of a crosslinker a hapten into a protein or macromolecules are disclosed. The compounds comprise bis heterofunctional crosslinkers or haptens containing a chromophoric group that is incorporated into the linker that is positioned between a reactive linking moiety and a biotin molecule. The incorporation of the crosslinker or hapten into a protein or other macromolecules may be detected by UV-Vis spectroscopy.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventor: Andrei POLUKHTIN
-
Publication number: 20140255401Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: Janssen Biotech, Inc.Inventors: Ellen Chi, Wilson Edwards, Chichi Huang, Wai-Ping Leung, Ronald Swanson, Alan Wickenden
-
Publication number: 20140255991Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.Type: ApplicationFiled: January 9, 2014Publication date: September 11, 2014Applicant: California Institute of TechnologyInventors: David A. Tirrell, Kristi Lynn Kiick
-
Publication number: 20140256643Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Inventors: Kristen JOHNSON, Jian SHI
-
Publication number: 20140248682Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: ApplicationFiled: February 14, 2014Publication date: September 4, 2014Applicant: MEDIMMUNE, LLCInventors: Changshou GAO, Chaity CHAUDHURY, Xiaotao YAO
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140242723Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: IDEXX Laboratories, Inc.Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Publication number: 20140242618Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Applicant: RANDOX LABORATORIES LIMITEDInventors: Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
-
Publication number: 20140242666Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr-Sr-O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Ser, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Publication number: 20140234360Abstract: Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed.Type: ApplicationFiled: September 28, 2012Publication date: August 21, 2014Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Joanna Kubler-Kielb, Jerry Keith, Rachel Schneerson, Zuzana Biesova
-
Publication number: 20140235532Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.Type: ApplicationFiled: February 21, 2014Publication date: August 21, 2014Applicant: Board of Trustees of Michigan State UniversityInventor: A. Mahdi Saeed
-
Publication number: 20140234365Abstract: The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Applicant: ALERE SAN DIEGO, INC.Inventor: Mariusz Banaszczyk
-
Publication number: 20140234311Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20140227717Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.Type: ApplicationFiled: February 10, 2014Publication date: August 14, 2014Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
-
Publication number: 20140228543Abstract: Modified and/or derivativized ?-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized ?-glucans are demonstrated.Type: ApplicationFiled: May 7, 2012Publication date: August 14, 2014Inventors: Nandita Bose, William J. Grossman, Michael Danielson, Andrew Magee, Paul Will, Kyle S. Michel, Vanessa A. Iiams, Xiaohong Qiu, Mary Antonysamy
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140205839Abstract: The subject of the present invention is a pure monomeric bovine serum albumin, a method of producing it characterised by the use column chromatography in resin and a method of identifying it using dynamic light scattering.Type: ApplicationFiled: May 6, 2012Publication date: July 24, 2014Applicant: WROCLAWSKIE CENTRUM BADAN EIT + SP Z O.O.Inventors: Jadwiga Pietkiewicz, Agnieszka Szydelko, Katarzyna Dzierzba, Regina Danielewicz, Magdalena Staniszewska, Arkadiusz Bartys, Andrzej Gamian
-
Publication number: 20140206020Abstract: Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Inventors: Johnny Valdez, SOON J. OH, BYUNG SOOK MOON
-
Publication number: 20140193842Abstract: Provided is a non-specific reaction inhibitor for achieving the accurate detection and quantitation of a trace component (a target substance) contained in a sample, in an immunoassay, by simply and effectively inhibiting a non-specific reaction associated with the measurement. The non-specific reaction inhibitor comprises a substance of the formula I: wherein R1 and R2 together form a double bond between carbons, to which they are respectively bonded directly, or R1 is a hydrogen atom and R2 is a group formed by removing H from an SH-group-containing compound, B is a support, and L is a spacer arm portion.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: MITSUBISHI CHEMICAL MEDIENCE CORPORATIONInventors: Yoshikazu Okamura, Shigeru Tashiro
-
Publication number: 20140187744Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. In one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino add sequence of SEQ ID NO: 4.Type: ApplicationFiled: August 9, 2012Publication date: July 3, 2014Applicant: NIPRO CORPORATIONInventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
-
Publication number: 20140187476Abstract: This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: June 25, 2013Publication date: July 3, 2014Applicant: BAOBAB PHARMACEUTICALS LIMITEDInventors: Dong XIE, He JIANG
-
Publication number: 20140179596Abstract: Provided herein are albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins and vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins and using these nucleic acids, vectors, and/or host cells also are provided. Further described are pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: August 13, 2013Publication date: June 26, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, Olivier Blondel
-
Publication number: 20140178902Abstract: The present invention relates to a method for detecting infections caused by or associated with siderophore-secreting microorganisms and kits and components used therein for carrying out the method. In one aspect the invention relates to a method for detecting siderophores and/or detecting infections caused by or associated with siderophore-secreting microorganisms in a biological sample of a subject, the method comprising providing a solid support having either bound siderophore or a conjugate thereof, or bound anti-siderophore antibody; reacting the bound siderophore or a conjugate thereof, with an anti-siderophore antibody, and a biological sample of a subject; or reacting the bound anti-siderophore antibody with a siderophore or conjugate thereof, and a biological sample of a subject; and detecting and/or quantifying the presence of the siderophore in the biological sample.Type: ApplicationFiled: May 16, 2012Publication date: June 26, 2014Applicant: NATIONAL UNIVERSITY OF IRELAND, MAYNOOTHInventors: John Martin Doyle, Kieran Walshe, Natasha Gordon, Kevin Kavanagh, Lorna Gallagher
-
Publication number: 20140154282Abstract: Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in a platform in order to form a two-stranded antigen suitable for immunization of a subject.Type: ApplicationFiled: January 26, 2012Publication date: June 5, 2014Inventors: Robert S. Hodges, Kathryn V. Holmes, Zhe Yan, Wendy Jeanne Hartsock, Zhaohui Qian, Brooke Elizabeth Bishop Hirsch
-
Publication number: 20140148390Abstract: The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides.Type: ApplicationFiled: July 4, 2012Publication date: May 29, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Haupts, Andreas Wilmen
-
Publication number: 20140148392Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: ApplicationFiled: August 9, 2011Publication date: May 29, 2014Applicant: MEDIMMUNE, LLCInventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
-
Publication number: 20140128326Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: November 8, 2013Publication date: May 8, 2014Applicants: Novozymes Biopharma DK A/S, University of OSLO, Novozymes Biopharma UK Limited, Novozymes A/SInventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
-
Publication number: 20140121357Abstract: A method for producing injectable pharmaceutical formulations of blood-derived protein materials includes the steps of fractioning the source material in a polymer/salt aqueous two-phase system in the presence of phenol, purifying the top phase of the system by means of precipitation with caprylic acid and purifying the bottom phase by means of thermocoagulation, increasing the purity of the materials in both phases through chromatography, removing viral particles by means of the nanofiltration of both preparations, and formulating, stabilizing, and packaging the resulting materials.Type: ApplicationFiled: April 8, 2011Publication date: May 1, 2014Applicant: UNIVERSIDAD DE COSTA RICAInventors: Alvaro Segura Ruiz, Mariángela Vargas Arroyo, Guillermo Leon Montero, Mauren Villalta Arrieta, Maria Herrera Vega, Yamileth Angulo Ugalde
-
Publication number: 20140107030Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: ApplicationFiled: May 6, 2013Publication date: April 17, 2014Applicant: VasGene Therapeutics, Inc.Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
-
Publication number: 20140107020Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Patent number: 8697650Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: GrantFiled: February 15, 2011Date of Patent: April 15, 2014Assignee: Medimmune, LLCInventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
-
Publication number: 20140099696Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: April 30, 2013Publication date: April 10, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Patent number: 8686225Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: GrantFiled: April 17, 2012Date of Patent: April 1, 2014Assignee: Ventria Bioscience Inc.Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20140086949Abstract: Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (PEG) units, and a protein carrier moiety. Immunoconjugates optionally include a conjugation moiety for conjugating the polypeptide hapten with a linker moiety or the protein carrier moiety and a linker moiety for conjugating the conjugation moiety with the protein carrier moiety.Type: ApplicationFiled: February 9, 2012Publication date: March 27, 2014Inventors: Kim D. Janda, Alexander V. Mayorov
-
Publication number: 20140056906Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
-
Publication number: 20140046027Abstract: The present invention concerns a method of modifying the surface of a cellulosic material, wherein a modifying compound is attached to the cellulosic material through a linker, which linker is a conjugate that has been activated by functionalization prior to adsorption to form an activated conjugate, and wherein the entire method is carried out in aqueous media, as well as an intermediate product suitable for attaching to a modifying compound, the intermediate product comprising said functionalized conjugate linker that has been adsorbed to a cellulosic material.Type: ApplicationFiled: March 7, 2012Publication date: February 13, 2014Applicant: AALTO UNIVERSITY FOUNDATIONInventors: Janne Laine, Sami Nummelin, Eero Kontturi, Olli Ikkala, Ilari Filpponen, Henna Rosilo
-
Publication number: 20140038893Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: August 1, 2013Publication date: February 6, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
-
Patent number: 8642542Abstract: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention.Type: GrantFiled: May 22, 2009Date of Patent: February 4, 2014Assignee: Novozymes Biopharma DK A/SInventor: David James Ballance
-
Publication number: 20140024807Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: March 28, 2013Publication date: January 23, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20140010850Abstract: Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue.Type: ApplicationFiled: September 16, 2013Publication date: January 9, 2014Applicant: Technion Research & Development Foundation LimitedInventors: Eyal ZUSSMAN, David Simhon, Shmuel Chervinsky, Abraham Katzir, Zvi Nevo, Yael Dror
-
Patent number: 8618257Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.Type: GrantFiled: September 7, 2007Date of Patent: December 31, 2013Assignee: Ambrx, Inc.Inventors: Joseph Sheffer, Thea Norman, Richard D. Dimarchi, Anna-Maria A. Hays Putnam, Feng Tian, Stephanie Chu, Denise Krawitz, Ho Sung Cho
-
Publication number: 20130344104Abstract: The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium difficile glycopolymer PS-II and a protein carrier. More specifically, the oligosaccharide is the hexasaccharide having the following formula (I) wherein R is a linker or spacer group. In a specific embodiment of the invention, R is (CH2)nNH2, with n being an integer from 2 to 50. The present invention also provides the use of said oligosaccharide and said oligosaccharide-protein conjugate for the treatment or prevention of a disease caused by the pathogen Clostridium difficile. In still further aspects, the present invention also provides a favourable method for preparing said oligosaccharide and said oligosaccharide-protein conjugate.Type: ApplicationFiled: March 7, 2012Publication date: December 26, 2013Inventors: Peter H. Seeberger, Matthias Oberli, Marie-Lyn Hecht
-
Publication number: 20130338342Abstract: A novel hemoglobin-albumin complex which has high stability of the oxygenated form, has high biocompatibility, and is easily prepared (synthesized), and an artificial plasma expander and an artificial oxygen carrier containing the complex are provided. The hemoglobin-albumin complex of the invention is characterized by having hemoglobin as the core, and albumin as the shell bound via a crosslinker to the above hemoglobin. Also, the artificial oxygen carrier of the invention is characterized by containing the hemoglobin-albumin complex of the invention.Type: ApplicationFiled: February 20, 2012Publication date: December 19, 2013Applicant: CHUO UNIVERSITYInventors: Teruyuki Komatsu, Daiki Tomita
-
Publication number: 20130324701Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Lewis T. WILLIAMS, Elizabeth BOSCH, Stephen K. DOBERSTEIN, Kevin HESTIR, Diane HOLLENBAUGH, Ernestine LEE, Minmin QIN QIN, Ali SADRA, Justin WONG, Ge WU, Hongbing ZHANG ZHANG
-
Publication number: 20130324700Abstract: A type of liquid chromatographic stationary phase and preparation method thereof, the bonding terminal of the chromatographic stationary phase is zwitterionic functional group. The preparation method includes the following steps, alkenyl or alkynyl silane is bonded onto the surface of silica based on the horizontal polymerization approach to obtain alkenyl- or alkynyl-modified silica. Then the thiol click reaction with zwitterionic compound containing thiol group is performed to obtain the zwitterionic hydrophilic interaction chromatographic stationary phase. The present stationary phase possesses both zwitterionic characteristics and excellent hydrophilicity. It can be widely applied in the separation of variety of samples.Type: ApplicationFiled: November 25, 2011Publication date: December 5, 2013Applicant: Dailian Institute of Chemical Physics, Chinese Aca of SciencesInventors: Xinmiao Liang, Aijin Shen, Zhimou Guo, Long Yu, Liwei Cao
-
Publication number: 20130310317Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: May 13, 2013Publication date: November 21, 2013Applicant: BRISTOL-MYERS SQUIBB COMPANYInventor: Bristol-Myers Squibb Company
-
Publication number: 20130310537Abstract: The invention relates to a method and a kit for preparing a radiopharmaceutical, the method comprising the steps: elution of a 68Ge/68Ga-Generator using hydrochloric acid as an eluent for obtaining a generator eluate comprising 68Gallium, feeding the generator eluate through a cation exchange cartridge, which collects the 68Gallium, separating the used eluent, eluting the 68Gallium from the cation exchange cartridge using a solution comprising sodium chloride and hydrochloric acid and feeding the resulting eluate into an aqueous precursor mixture comprising at least a labelling precursor thereby forming a reaction solution.Type: ApplicationFiled: May 18, 2012Publication date: November 21, 2013Applicant: Zentralklinik Bad Berka GmbHInventor: Dirk Müller
-
Publication number: 20130309169Abstract: The present invention relates to a sentinel lymph node marker comprising an albumin; a radioactive isotope and/or near infrared dye which is bound to the albumin; and a visible dye which is bound to the albumin, a preparation method thereof, a kit for multimode imaging of a sentinel lymph node to prepare the sentinel lymph node marker, and a method for multimode imaging of a sentinel lymph node using the same. The sentinel lymph node marker of the invention remains in the sentinel lymph node for a long period of time and allows for multimode imaging of the sentinel lymph node. Thus, using this marker the sentinel lymph node can be accurately identified in vivo by near infrared imaging and/or gamma imaging without incision of skin, and the location of the identified sentinel lymph node can be precisely identified with the naked eye during a surgical operation of removing the identified sentinel lymph node.Type: ApplicationFiled: August 16, 2011Publication date: November 21, 2013Applicant: NATIONAL CANCER CENTERInventors: Seok Ki Kim, Se Hun Kang, Seo Il Kim, Young Sang Kim, Nam Suk Baek, Jin Hee Noh